Specialty Generics Market Trends 2024 Industry Demand, Revenue Growth and Forecast to 2032

The latest report by IMARC Group, titled “Specialty Generics Market Report by Route of Administration (Injectables, Oral, and Others), Indication (Oncology, Autoimmune Diseases, Infectious Diseases, and Others), Distribution channel (Retail Pharmacies, Specialty Pharmacies, Hospital Pharmacies), and Region 2024-2032“, The global specialty generics market size reached US$ 74.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 172.5 Billion by 2032, exhibiting a growth rate (CAGR) of 9.4% during 2024-2032.

Customized generic medications, known as specialty generics, are created to provide affordable alternatives to high-cost, brand-name specialty drugs. These specialty drugs are usually prescribed to manage intricate and ongoing health issues, such as cancer, autoimmune diseases, and rare inherited conditions. The goal of specialty generics is to deliver the same healing benefits as their brand-name equivalents at a lower cost. Unlike traditional generics, which simply duplicate the chemical makeup of the original drug, specialty generics often require more sophisticated manufacturing techniques to reproduce the complex molecular structures found in specialty drugs, including biosimilars, which are generic versions of biologic medications derived from living organisms.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/specialty-generics-market/requestsample

Specialty Generics Market Trends and Drivers:

The specialty generics market is driven significantly by the necessity to control rising healthcare expenses. Specialty generics present a more affordable option compared to expensive brand-name specialty drugs, enhancing accessibility for patients and healthcare systems internationally. Furthermore, with the aging global population, there is a growing occurrence of chronic and intricate conditions like cancer, diabetes, and autoimmune disorders. This demographic boosts the need for specialty medications and their generic versions. Moreover, the expiration of patents for various specialty drugs enables generic companies to join the market, offering more cost-effective choices. The expiration of patents on branded drugs opens the door for specialty generics to enter the market. Additionally, the growing number of people suffering from chronic illnesses demands a wider range of treatment choices. Specialty generics offer patients a more affordable way to access life-changing medications for conditions like rheumatoid arthritis, multiple sclerosis, and HIV. As pharmaceutical companies and generic drug manufacturers compete to break into the specialty generics market, they are driven to innovate and lower prices, ultimately benefiting patients. Moreover, the expansion of healthcare services, especially in emerging markets, is fueling demand for specialty generics as they provide cost-effective solutions for complex health issues. Furthermore, regulatory bodies globally are implementing rigorous standards for approving specialty generics, guaranteeing their safety, quality, and effectiveness, which in turn boosts confidence in these medications.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Route of Administration:

• Injectables
• Oral
• Others

Breakup by Indication:

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Others

Breakup by Distribution channel:

• Retail Pharmacies
• Specialty Pharmacies
• Hospital Pharmacies

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Competitive Landscape with Key Player:

• Teva Pharmaceuticals Industries
• Akorn, Inc.
• Mylan N.V.
• Mallinckrodt
• Sandoz International GmbH
• Pfizer, Inc.
• Sun Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals
• Apotex Corp.
• Endo International plc

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145